skip to Main Content

Janssen Announces Unblinding of Phase 3 CARTITUDE-4 Study of CARVYKTI® (cilta-cel) as Primary Endpoint Met in Treatment of Patients with Relapsed and Refractory Multiple Myeloma #mmsm #cellulartherapy #CARTsm https://www.prnewswire.com/news-releases/janssen-announces-unblinding-of-phase-3-cartitude-4-study-of-carvykti-cilta-cel-as-primary-endpoint-met-in-treatment-of-patients-with-relapsed-and-refractory-multiple-myeloma-301732398.html

An inspiration for the new year! Dr. Alex Herrera was on the @cityofhope "Expanding Hope" float in the #roseparade2023 . The mother of one of his patients walked alongside the float for 2.5 miles throwing him kisses to give him thanks and gratitude. http://bit.ly/3vQX2Do

Excited that our efforts, led by @tal_sella and @AnnPartridgeMD, to study patients’ perspectives on testing for #CHIP is now published @BloodAdvances https://ashpublications.org/bloodadvances/article/6/24/6151/486674/Patient-perspectives-on-testing-for-clonal

Load More...
Back To Top